Rocket Lab's Neutron Uncertainty Overshadows a Steady Electron Cadence

Rocket Lab faces Neutron delays and a lost NASA contract, but Electron launches continue. Stock down 21% in a month, analysts split.

The gap between what Rocket Lab executes today and what investors must simply take on faith for tomorrow has rarely been wider. The company's workhorse Electron rocket keeps flying with mechanical reliability, yet the stock's trajectory is increasingly dictated by a vehicle that has yet to leave the ground.

That vehicle, the medium-lift Neutron, is now widely expected to miss its 2026 debut window entirely. Market observers reported on Friday that the first flight could slip into 2027, with the company having offered no firm launch date. For a stock already nursing steep losses, the timeline drift cuts to the heart of the growth thesis: Neutron is the vehicle meant to carry Rocket Lab beyond small-satellite rideshare work and into the realm of large constellations and government contracts — territory where SpaceX currently faces little serious competition.

A Lost NASA Contract Adds to the Pressure

The timing could hardly be worse. On Thursday, NASA awarded a Mars communications contract worth roughly $700 million to Blue Origin, passing over Rocket Lab in what multiple market reports framed as a competitive defeat. While not existential — the company's core launch business remains intact — the decision signals that Rocket Lab's bid to be recognized as a full-fledged systems provider, not merely a launch vendor, still faces formidable hurdles.

Together, the lost contract and the slipping Neutron schedule have sharpened questions about near-term growth, even as the operational story hums along undisturbed.

Electron Keeps Delivering

The operational side of the ledger remains a portrait of consistency. On September 2, Rocket Lab completed its 94th Electron launch, carrying a StriX Earth-observation satellite for Japanese customer Synspective. The mission, which had been pushed back a day by strong winds, marked the company's 15th launch of 2026. Rocket Lab's track record with Synspective remains flawless, and media reports indicate the company has booked 16 additional Synspective missions through 2030 — a pipeline that secures Electron's utilization well into the decade, independent of Neutron's fate.

That recurring revenue base stands in contrast to the signals emanating from the executive suite. CFO Adam C. Spice disposed of 140,157 shares on September 2 at a weighted average price of $62.63, a transaction worth approximately $8.8 million. Routine insider sales of this kind are rarely alarming in isolation, but they land at a moment when the stock is already under duress.

A Stock Caught Between Two Narratives

The market's verdict is visible in the price action. The shares recently closed at €56.70, up 2.4% on the day — a modest bounce following a month that erased roughly 19% of the stock's value. The longer-term picture is more forgiving: a 40% gain over twelve months suggests the broader growth story retains believers among patient investors. Yet the nearer-term damage is unmistakable. Over the past 30 days, the stock has shed about 21%, leaving it down 10% year-to-date and roughly 59% below its 52-week high of €133.80. Trading at €55.30, the shares sit well beneath their 200-day moving average of €69.99 — a technical signal that the medium-term trend remains firmly negative.

Analyst sentiment reflects the same tension. Berenberg initiated coverage on September 2 with a buy rating and an $83 price target, a notably bullish entry point. Just days earlier, on August 31, both Bank of America Securities and Roth Capital trimmed their price targets — to $110 from $115 and to $110 from $130, respectively — while reaffirming buy recommendations. The pattern suggests that even established Rocket Lab optimists have recalibrated their near-term expectations around Neutron's timeline without abandoning their fundamental conviction.

Institutional activity tells a similar story of divided opinion. ARK Invest funds purchased roughly 504,799 shares worth about $31.6 million during the same period, a deliberate bet against the prevailing short-term skepticism. Meanwhile, the CFO's sale — modest in size but symbolically awkward — feeds a narrative of a stock torn between operational solidity and strategic uncertainty.

The Core Question for Investors

Rocket Lab now presents investors with an unusually stark choice of framings. One view holds that this is a dependable space contractor with a proven small-launch vehicle, recurring customer relationships, and a full manifest through the end of the decade — a business that can be valued on its current merits. The other view treats the company as essentially a call option on Neutron, whose value will only crystallize once a concrete launch date materializes.

The recent price-target cuts suggest the market is slowly gravitating toward the latter interpretation, discounting the stock for timeline risk while stopping short of abandoning the thesis altogether. Electron pays for today; Neutron determines how much bigger tomorrow gets. For now, investors are left waiting for a date that keeps receding.